Phase Ib Trial of Teclistamab and Iberdomide in Relapsed/Refractory Multiple Myeloma
A phase Ib trial is underway to evaluate the safety and dosing of iberdomide combined with teclistamab for relapsed or refractory multiple myeloma.
Asset / Drug
Drug and asset intelligence for Teclistamab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.